These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25734146)

  • 1. Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin.
    Howe JA; Long J; Black S; Chase R; McMonagle P; Curry S; Thompson S; DiNubile MJ; Howe AY
    Open Forum Infect Dis; 2014 Sep; 1(2):ofu078. PubMed ID: 25734146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.
    Barnard RJ; Howe JA; Ogert RA; Zeuzem S; Poordad F; Gordon SC; Ralston R; Tong X; Sniukiene V; Strizki J; Ryan D; Long J; Qiu P; Brass CA; Albrecht J; Burroughs M; Vuocolo S; Hazuda DJ
    Virology; 2013 Sep; 444(1-2):329-36. PubMed ID: 23876458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
    Ogert RA; Howe JA; Vierling JM; Kwo PY; Lawitz EJ; McCone J; Schiff ER; Pound D; Davis MN; Gordon SC; Ravendhran N; Rossaro L; Jacobson IM; Ralston R; Chaudhri E; Qiu P; Pedicone LD; Brass CA; Albrecht JK; Barnard RJ; Hazuda DJ; Howe AY
    Antivir Ther; 2013; 18(3):387-97. PubMed ID: 23406826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C.
    Howe AY; Long J; Nickle D; Barnard R; Thompson S; Howe J; Alves K; Wahl J
    Antiviral Res; 2015 Jan; 113():71-8. PubMed ID: 25446895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
    Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
    Larrat S; Vallet S; David-Tchouda S; Caporossi A; Margier J; Ramière C; Scholtes C; Haïm-Boukobza S; Roque-Afonso AM; Besse B; André-Garnier E; Mohamed S; Halfon P; Pivert A; LeGuillou-Guillemette H; Abravanel F; Guivarch M; Mackiewicz V; Lada O; Mourez T; Plantier JC; Baazia Y; Alain S; Hantz S; Thibault V; Gaudy-Graffin C; Bouvet D; Mirand A; Henquell C; Gozlan J; Lagathu G; Pronier C; Velay A; Schvoerer E; Trimoulet P; Fleury H; Bouvier-Alias M; Brochot E; Duverlie G; Maylin S; Gouriou S; Pawlotsky JM; Morand P
    J Clin Microbiol; 2015 Jul; 53(7):2195-202. PubMed ID: 25926499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
    Lenz O; Verbinnen T; Fevery B; Tambuyzer L; Vijgen L; Peeters M; Buelens A; Ceulemans H; Beumont M; Picchio G; De Meyer S
    J Hepatol; 2015 May; 62(5):1008-14. PubMed ID: 25445400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH; Gordon LA; Fung HB
    Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
    Kwo PY; Lawitz EJ; McCone J; Schiff ER; Vierling JM; Pound D; Davis MN; Galati JS; Gordon SC; Ravendhran N; Rossaro L; Anderson FH; Jacobson IM; Rubin R; Koury K; Pedicone LD; Brass CA; Chaudhri E; Albrecht JK;
    Lancet; 2010 Aug; 376(9742):705-16. PubMed ID: 20692693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
    Kanda T; Nakamoto S; Sasaki R; Nakamura M; Yasui S; Haga Y; Ogasawara S; Tawada A; Arai M; Mikami S; Imazeki F; Yokosuka O
    Int J Med Sci; 2016; 13(4):310-5. PubMed ID: 27076789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM; Marcellin P; Zeuzem S; Sulkowski MS; Esteban R; Poordad F; Bruno S; Burroughs MH; Pedicone LD; Boparai N; Deng W; DiNubile MJ; Gottesdiener KM; Brass CA; Albrecht JK; Bronowicki JP
    Hepatology; 2012 Aug; 56(2):567-75. PubMed ID: 22619063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage.
    Welsch C; Haselow K; Gouttenoire J; Schneider M; Morikawa K; Martinez Y; Susser S; Sarrazin C; Zeuzem S; Antes I; Moradpour D; Lange CM
    J Hepatol; 2015 Apr; 62(4):779-84. PubMed ID: 25463536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.
    Dietz J; Rupp D; Susser S; Vermehren J; Peiffer KH; Filmann N; Bon D; Kuntzen T; Mauss S; Grammatikos G; Perner D; Berkowski C; Herrmann E; Zeuzem S; Bartenschlager R; Sarrazin C
    PLoS One; 2016; 11(6):e0156731. PubMed ID: 27281344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
    Hsieh MH; Yeh ML; Su TH; Liu TW; Huang CF; Huang CI; Wang SC; Huang JF; Dai CY; Kao JH; Chuang WL; Chen PJ; Liu CJ; Yu ML
    J Formos Med Assoc; 2018 Jun; 117(6):497-504. PubMed ID: 28694000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
    De Meyer S; Dierynck I; Ghys A; Beumont M; Daems B; Van Baelen B; Sullivan JC; Bartels DJ; Kieffer TL; Zeuzem S; Picchio G
    Hepatology; 2012 Dec; 56(6):2106-15. PubMed ID: 22806681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.